BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7606820)

  • 1. Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells.
    Tainsky MA; Bischoff FZ; Strong LC
    Cancer Metastasis Rev; 1995 Mar; 14(1):43-8. PubMed ID: 7606820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
    Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
    Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts.
    Gollahon LS; Kraus E; Wu TA; Yim SO; Strong LC; Shay JW; Tainsky MA
    Oncogene; 1998 Aug; 17(6):709-17. PubMed ID: 9715272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No point mutation of Ha-ras or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants.
    Sun Y; Nakamura K; Hegamyer G; Dong Z; Colburn N
    Mol Carcinog; 1993; 8(1):49-57. PubMed ID: 8352891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immortal, telomerase-negative cell lines derived from a Li-Fraumeni syndrome patient exhibit telomere length variability and chromosomal and minisatellite instabilities.
    Tsutsui T; Kumakura S; Tamura Y; Tsutsui TW; Sekiguchi M; Higuchi T; Barrett JC
    Carcinogenesis; 2003 May; 24(5):953-65. PubMed ID: 12771041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family.
    Evans SC; Mims B; McMasters KM; Foster CJ; deAndrade M; Amos CI; Strong LC; Lozano G
    Hum Genet; 1998 Jun; 102(6):681-6. PubMed ID: 9703430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risks from germ line tumor suppressor gene mutations.
    Frebourg T; Malkin D; Friend S
    Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma.
    Sameshima Y; Tsunematsu Y; Watanabe S; Tsukamoto T; Kawa-ha K; Hirata Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
    J Natl Cancer Inst; 1992 May; 84(9):703-7. PubMed ID: 1569604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RECQL4 and p53 potentiate the activity of polymerase γ and maintain the integrity of the human mitochondrial genome.
    Gupta S; De S; Srivastava V; Hussain M; Kumari J; Muniyappa K; Sengupta S
    Carcinogenesis; 2014 Jan; 35(1):34-45. PubMed ID: 24067899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
    Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
    Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
    Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
    Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families.
    Boyle JM; Mitchell EL; Greaves MJ; Roberts SA; Tricker K; Burt E; Varley JM; Birch JM; Scott D
    Br J Cancer; 1998 Jun; 77(12):2181-92. PubMed ID: 9649131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
    Stein T; Crighton D; Boyle JM; Varley JM; White RJ
    Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.